参考文献/References:
[1] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J]. 中国循环杂志,2019,34(3):209-220.
[2] Volpe M,Tocci G,Battistoni A,et al. Angiotensin Ⅱ receptor blocker neprilysin inhibitor (ARNI):new avenues in cardiovascular therapy[J]. High Blood Press Cardiovasc Prev,2015,22(3):241-246.
[3] Vardeny O,Miller R,Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure[J]. JACC Heart Fail,2014,2(6):663-670.
[4] Kusaka H,Sueta D,Koibuchi N,et al. LCZ696,angiotensin Ⅱ receptor-neprilysin inhibitor,ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone[J]. Am J Hypertens,2015,28(12):1409-1417.
[5] Ruilope LM,Dukat A,B?hm M,et al. Blood-pressure reduction with LCZ696,a novel dual-acting inhibitor of the angiotensin Ⅱ receptor and neprilysin:a randomised,double-blind,placebo-controlled,active comparator study[J]. Lancet,2010,375(9722):1255-1266.
[6] Kario K,Sun N,Chiang FT,et al. Efficacy and safety of LCZ696,a first-in-class angiotensin receptor neprilysin inhibitor,in Asian patients with hypertension:a randomized,double-blind,placebo-controlled study[J]. Hypertension,2014,63(4):698-705.
[7] Supasyndh O,Sun N,Kario K,et al. Long-term(52-week) safety and efficacy of sacubitril/valsartan in Asian patients with hypertension[J]. Hypertens Res,2017,40(5):472-476.
[8] Aronow WS. Approaches for the Management of Resistant Hypertension in 2020[J]. Curr Hypertens Rep,2020,22(1):3.
[9] Li Q,Li L,Wang F,et al. Effect and safety of LCZ696 in the treatment of hypertension:a meta-analysis of 9 RCT studies[J]. Medicine,2019,98(28):e16093.
[10]Ye L,Yang X,Hu J,et al. Impact of antihypertensive agents on arterial stiffness in hypertensive patients[J]. Int J Cardiol,2018,273:207-212.
[11]廖梦阳,袁璟,廖玉华.开启心力衰竭治疗的新纪元——3类神经激素拮抗剂的应用[J]. 临床心血管病杂志,2019,35(7):583-585.
[12]McMurray JJ,Packer M,Desai AS,et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM‐HF)[J]. Eur J Heart Fail,2014,16(7):817-825.
[13]McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.
[14]Solomon SD,Zile M,Pieske B,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial[J]. Lancet,2012,380(9851):1387-1395.
[15]Januzzi JL,Prescott MF,Butler J,et al. Association of change in N-terminal pro-B-type Natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction[J]. JAMA,2019,322(11):1-11.
[16]Tan NY,Sangaralingham LR,Sangaralingham SJ,et al. Comparative effectiveness of sacubitril-valsartan versus ACE/ARB therapy in heart failure with reduced ejection fraction[J]. JACC Heart Fail,2020,8(1):43-54.
[17]Velazquez EJ,Morrow DA,DeVore AD,et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med,2019,380(6):539-548.
[18]Senni M,McMurray JJ,Wachter R,et al. Initiating sacubitril/valsartan (LCZ696) in heart failure:results of TITRATION,a double‐blind, randomized comparison of two uptitration regimens[J]. Eur J Heart Fail,2016,18(9):1193-1202.
[19]Eckardt L,Haverkamp W,Johna R,et al. Arrhythmias in heart failure:current concepts of mechanisms and therapy[J]. J Cardiovasc Electrophysiol,2000,11(1):106-117.
[20]Martens P,Nuyens D,Rivero-Ayerza M,et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2019,108(10):1074-1082.
[21]de Diego C,González-Torres L,Nú?ez JM,et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices[J]. Heart Rhythm,2018,15(3):395-402.
[22]Madrid AH,Marín IM,Escobar Cervantes C,et al. Prevention of recurrences in patients with lone atrial fibrillation.The dose-dependent effect of angiotensin Ⅱ receptor blockers[J]. J Renin Angiotensin Aldosterone Syst,2004,5(3):114-120.
[23]Yin Y,Dalal D,Liu Z,et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation [J]. Eur Heart J,2006,27(15):1841-1846.
[24]张舒珊.心房颤动与钠尿肽家族最新研究进展[J].心血管病学进展,2018,39(3):442-445.
[25]Hobbs AJ,Moyes AJ,Baliga RS,et al. Neprilysin inhibition for pulmonary arterial hypertension:a randomized,double‐blind,placebo-controlled, proof-of-concept trial[J]. Br J Pharmacol,2019,176(9):1251-1267.
[26]Clements RT,Vang A,Fernandez-Nicolas A,et al. Treatment of pulmonary hypertension with angiotensin Ⅱ receptor blocker and neprilysin inhibitor sacubitril/valsartan[J]. Circ Heart Fail,2019,12(11):e005819.
[27]de Simone V,Guarise P,Zanotto G,et al. Reduction in pulmonary artery pressures with use of sacubitril/valsartan[J]. J Cardiol Cases,2019,20(5):187-190.
[28]Corazza F,Ceccarelli A,Vitale G,et al. Changes in hemodynamic profile in patients with severe systolic dysfunction treated with sacubitril-valsartan[J]. Eur J Heart Fail,2019,21(suppl 1):422.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(9):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(9):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(9):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(9):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]潘东 罗勇.沙库巴曲缬沙坦在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,(2):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
PAN DongLUO Yong.Sacubitril/valsartan in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2020,(9):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
[12]费美莹 姜东炬.心力衰竭药物沙库巴曲缬沙坦的研究进展[J].心血管病学进展,2020,(2):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
FEI Meiying J IANG Dongju.Heart Failure Drug Sacubitril Valsartan[J].Advances in Cardiovascular Diseases,2020,(9):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
[13]穆耶赛尔·玉苏普 芦颜美 汤宝鹏.沙库巴曲缬沙坦对心力衰竭患者认知功能的影响[J].心血管病学进展,2023,(8):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]
Muyassar·Yusup,LU Yanmei,TANG Baopeng.Effect of Sacubritil/Valsartan on Cognitive Function in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2023,(9):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]